{"organizations": [], "uuid": "7b38d160552928bc9d10ead206bcc2d98f40054f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-eloxx-pharmaceuticals-announces-or/brief-eloxx-pharmaceuticals-announces-orphan-drug-designation-for-elx-02-for-treatment-of-cystinosis-idUSASC09Y2M", "country": "US", "domain_rank": 408, "title": "BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-27T19:42:00.000+03:00", "replies_count": 0, "uuid": "7b38d160552928bc9d10ead206bcc2d98f40054f"}, "author": "", "url": "https://www.reuters.com/article/brief-eloxx-pharmaceuticals-announces-or/brief-eloxx-pharmaceuticals-announces-orphan-drug-designation-for-elx-02-for-treatment-of-cystinosis-idUSASC09Y2M", "ord_in_thread": 0, "title": "BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-eloxx pharmaceuticals announces orphan-drug", "sentiment": "negative"}, {"name": "eloxx pharmaceuticals inc", "sentiment": "none"}, {"name": "fda", "sentiment": "none"}, {"name": "treatment of cystinosis reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27, 2018 / 4:42 PM / Updated 16 minutes ago BRIEF-Eloxx Pharmaceuticals Announces Orphan-Drug Designation For ELX-02 For Treatment Of Cystinosis Reuters Staff 1 Min Read\nApril 27 (Reuters) - Eloxx Pharmaceuticals Inc:\n* ELOXX PHARMACEUTICALS ANNOUNCES FDA GRANT OF ORPHAN-DRUG DESIGNATION FOR INVESTIGATIONAL DRUG ELX-02 FOR TREATMENT OF CYSTINOSIS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-27T19:42:00.000+03:00", "crawled": "2018-04-27T20:04:00.032+03:00", "highlightTitle": ""}